Rylaze Approval May Have Been Expected But Could Drive $226M In Sales For Jazz Pharmaceuticals (JAZZ), PT Increased at Jefferies
Tweet Send to a Friend
Jefferies analyst David Steinberg raised the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $220.00 (from $214.00) noting that the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
